Skip to main content

RxNews®

Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.

Fasenra® (benralizumab) – New indication

September 18, 2024 -  AstraZeneca announced the FDA approval of Fasenra (benralizumab), for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

Download PDF

Rx navigation